Baldwin Investment Management LLC Has $1.16 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Key Points

• Baldwin Investment Management LLC significantly increased its stake in Pfizer Inc. by 155.4%, acquiring an additional 27,940 shares and bringing its total holdings to 45,918 shares valued at approximately $1.16 million.
• Several institutional investors have made substantial moves in Pfizer's stock, with Pacer Advisors Inc. boosting its holdings by 856.8% to over 20 million shares, reflecting a broader trend of institutional interest in the biopharmaceutical company.
• Pfizer plans to pay a quarterly dividend of $0.43 per share on September 2nd, with an annualized yield of 6.94%, despite a high dividend payout ratio of 124.64%.

Baldwin Investment Management LLC raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 155.4% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 45,918 shares of the biopharmaceutical company's stock after purchasing an additional 27,940 shares during the period. Baldwin Investment Management LLC's holdings in Pfizer were worth $1,164,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Pacer Advisors Inc. boosted its stake in shares of Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after buying an additional 17,957,928 shares during the period. Starboard Value LP purchased a new stake in Pfizer during the fourth quarter worth approximately $407,730,000. Assenagon Asset Management S.A. lifted its stake in Pfizer by 307.5% during the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after purchasing an additional 7,581,030 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Pfizer by 7.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the last quarter. Finally, APG Asset Management N.V. lifted its stake in Pfizer by 1,106.0% during the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company's stock worth $143,967,000 after purchasing an additional 5,153,257 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on PFE shares. UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. BMO Capital Markets dropped their target price on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective on the stock. Citigroup boosted their target price on Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Finally, Bank of America boosted their target price on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $28.55.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.39 during mid-day trading on Thursday, hitting $23.43. The company had a trading volume of 31,872,028 shares, compared to its average volume of 45,123,859. The stock has a market cap of $133.18 billion, a price-to-earnings ratio of 16.95, a PEG ratio of 0.88 and a beta of 0.58. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.32. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The firm's 50 day simple moving average is $24.35 and its two-hundred day simple moving average is $24.62.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period last year, the firm earned $0.82 EPS. The firm's revenue was down 7.8% compared to the same quarter last year. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.34%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.